XML 77 R54.htm IDEA: XBRL DOCUMENT v3.8.0.1
Collaborative Research, Development and License Agreements - Additional Information (Detail) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Nov. 30, 2016
Jun. 30, 2007
Mar. 31, 2017
Dec. 31, 2016
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2017
Nov. 30, 2017
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Liability related to unused development funding       $ 11,192,000 $ 11,192,000   $ 9,695,000  
Maximum                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Additional milestone payments eligible to be received based on achievement of certain development and regulatory objectives             100,000,000  
Astra Zeneca                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Milestone payments earned $ 7,200,000       7,200,000      
Unused development funding advanced by AstraZeneca $ 7,400,000              
Milestone revenue recognition       $ 7,200,000 $ 103,000 $ 1,635,000    
Unused development funding paid     $ 200,000          
Liability related to unused development funding             0  
Coley Pharmaceutical Group, Inc.                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Intangible asset               $ 2,500,000
Agreement termination date   2018-02            
Expected milestone payments prior to termination             0  
Coley Pharmaceutical Group, Inc. | Accounts Payable                
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]                
Payment due included in accounts payable             $ 2,500,000